Material Change Report
Lorus Therapeutics Inc. (“ Lorus ”)
2 Meridian Road
May 25, 2010
The press release reporting the material change was issued by Lorus on May 25,
2010 in Canada through Marketwire and is attached hereto as Schedule “A”.
The news release issued on May 25, 2010 by Lorus announced that Lorus had
completed a consolidation of its issued and outstanding common shares on the
basis of one (1) post-consolidation common share for every thirty (30) pre-
consolidation common shares.
The Company expects the common shares to begin trading on the Toronto Stock
Exchange and the OTC Bulletin Board in the United States on a consolidation-
adjusted basis on or about May 31, 2010. Letters of transmittal providing for the
exchange of certificates representing pre-consolidation common shares for
certificates representing post-consolidation shares are expected to be delivered to
shareholders on or about May 26, 2010.
For more information regarding the material change, please see the news release
filed on May 25, 2010 attached hereto as Schedule “A.”
For further information please contact:
Lorus Therapeutics Inc.
Dr. Saeid Babaei
(416) 798-1200 ext. 490.
Name and Address of Company
Date of Material Change
Summary of Material Change
Full Description of Material Change
Reliance on subsection 7.1(2) or (3) of National Instrument 51-102
Date of Report
May 31, 2010
Lorus Therapeutics Announces Completion of Share Consolidation
TORONTO, CANADA - May 25, 2010 - Lorus Therapeutics Inc. (TSX: LOR; OTCBB: LRUSF)
(“Lorus” or the “Company”), a biopharmaceutical company specializing in the research and